30
Participants
Start Date
November 9, 2021
Primary Completion Date
August 22, 2027
Study Completion Date
October 23, 2027
REGN5093-M114
Administered by intravenous (IV) infusion
Cemiplimab
Administered by IV infusion
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building, Baltimore
Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building, Baltimore
Next Virginia, Fairfax
MUSC Hollings Cancer Center, Charleston
Henry Ford Hospital, Henry Ford Cancer Institute, Detroit
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Hospital Anshutz Outpatient Pavillion, Denver
University of California Irvine School of Medicine - Suite 400, Room 407, Orange
Dana-Farber Cancer Institute, Boston
Regeneron Pharmaceuticals
INDUSTRY